A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

por Rossi, J-F, Négrier, S, James, N D, Kocak, I, Hawkins, R, Davis, H, Prabhakar, U, Qin, X, Mulders, P, Berns, B
Publicado 2010

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma

por Larkin, J M G, Ferguson, T R, Pickering, L M, Edmonds, K, James, M G, Thomas, K, Banerji, U, Berns, B, de Boer, C, Gore, M E
Publicado 2010